[18F]FAPI-42 PET/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET/CT

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 71 209-249

[2] Ferlay J(2018)Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer J Clin Oncol. 36 438-445

[3] Siegel RL(2018)Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer JAMA Surg. 153 1098-1104

[4] Laversanne M(2016)2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid. 26 1-133

[5] Soerjomataram I(2014)Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy Proteomics Clin Appl. 8 454-463

[6] Jemal A(2019)(68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer J Nucl Med Off Publ Soc Nucl Med. 60 801-805

[7] Shen X(2016)Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma Tumour Biol. 37 8197-8207

[8] Zhu G(2021)Cancer-associated fibroblasts positively correlate with dedifferentiation and aggressiveness of thyroid cancer Onco Targets Ther. 14 1205-1217

[9] Liu R(2022)Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study Thyroid. 32 65-77

[10] Viola D(2019)68 Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers J Nucl Med. 60 386-392

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 71 209-249

[2] Ferlay J(2018)Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer J Clin Oncol. 36 438-445

[3] Siegel RL(2018)Association of radioactive iodine administration after reoperation with outcomes among patients with recurrent or persistent papillary thyroid cancer JAMA Surg. 153 1098-1104

[4] Laversanne M(2016)2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer Thyroid. 26 1-133

[5] Soerjomataram I(2014)Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy Proteomics Clin Appl. 8 454-463

[6] Jemal A(2019)(68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer J Nucl Med Off Publ Soc Nucl Med. 60 801-805

[7] Shen X(2016)Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma Tumour Biol. 37 8197-8207

[8] Zhu G(2021)Cancer-associated fibroblasts positively correlate with dedifferentiation and aggressiveness of thyroid cancer Onco Targets Ther. 14 1205-1217

[9] Liu R(2022)Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study Thyroid. 32 65-77

[10] Viola D(2019)68 Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers J Nucl Med. 60 386-392